Lantern Pharma Inc (LTRN)
5.90
-0.24
(-3.91%)
USD |
NASDAQ |
May 20, 14:34
Lantern Pharma SG&A Expense (Quarterly): 1.481M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 1.481M |
December 31, 2023 | 1.304M |
September 30, 2023 | 1.314M |
June 30, 2023 | 1.632M |
March 31, 2023 | 1.733M |
December 31, 2022 | 1.575M |
September 30, 2022 | 1.443M |
June 30, 2022 | 1.406M |
March 31, 2022 | 1.406M |
December 31, 2021 | 1.349M |
September 30, 2021 | 1.184M |
Date | Value |
---|---|
June 30, 2021 | 1.314M |
March 31, 2021 | 1.173M |
December 31, 2020 | 1.548M |
September 30, 2020 | 1.101M |
June 30, 2020 | 0.6764M |
March 31, 2020 | 0.3402M |
December 31, 2019 | 0.4977M |
September 30, 2019 | 0.4413M |
June 30, 2019 | 0.2681M |
March 31, 2019 | 0.2679M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.2681M
Minimum
Jun 2019
1.733M
Maximum
Mar 2023
1.159M
Average
1.314M
Median
SG&A Expense (Quarterly) Benchmarks
Eyenovia Inc | 3.637M |
Cassava Sciences Inc | 3.701M |
Alpine Immune Sciences Inc | 7.271M |
Clearside Biomedical Inc | 2.824M |
Poseida Therapeutics Inc | 9.798M |